-
-
For years HIV experts and advocates have warned that unless federal funding for the AIDS Drug Assistance Program (ADAP) was ramped up significantly then thousands of Americans could be left off the roles and face risks of illness and death without dependable access to antiretroviral therapy (ART).
-
The Centers for Disease Control and Prevention is developing formal guidelines on preexposure prophylaxis (PrEP) to prevent HIV in men who have sex with men (MSM). In the interim, the CDC has issued the following recommendations to guide clinical practice.
-
The once rare but very real risk of occupational HIV transmission continues to fade in the face of a host of prevention measures that include needle safety devices and post-exposure prophylaxis.
-
With unprecedented numbers of HIV patients pushed onto waiting lists to receive antiretroviral (ART) drugs from AIDS Drug Assistance Programs (ADAPs), the bottom rung safety nets are barely holding, experts say.
-
HIV clinicians are seeing increasing numbers of patients who are developing cancers associated with infectious agents, particularly in the areas of the oropharynx and genitals, researchers say.
-
While the human papillomavirus (HPV) vaccine has been approved for use in men, how many are open to receiving it? New research indicates men might be more willing to receive vaccination when they learn the vaccine can prevent cancer.
-
In this study, 783 HIV-infected Indian mother-infant pairs participated in a randomized clinical trial comparing NVP given for 6 weeks vs. single-dose NVP to prevent MTCT of HIV among breast-fed infants.
-
Genentech has issued the following Dear Healthcare Professional letter for users of Fuzeon and certain other injection products:
-
